enhancing life by focussing on cell death
About us
Apop Biosciences Pty Ltd was established in October 2016 by founding director and medical researcher Dr Peter Wookey. We named our company APOP Biosciences after the major form of Programmed Cell Death (PCD) Apoptosis.
Dr Wookey discovered and developed the proprietary calcitonin receptor antibodies and protected the Intellectual Property in two patents. The IP is fully owned by Apop Biosciences.
Executive Leadership
-
Elpis Barons
CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR
Elpis is a highly skilled international healthcare business and research executive. She has worked with and led early to mid-stage enterprises for over 30 years across the Life Sciences, MedTech and BioTech sectors.
Her proven leadership skills and extensive experience in commercialising early stage technologies, managing operations, building teams and developing strategic partnerships, span across a variety of sectors.
Elpis brings a breadth of experience to the team as a successful business owner. She is an advisory board member to early stage companies, mentor to academic institutions and US-based global Health/MedTech accelerators, and a judge of applicants to these programmes.
-
Dr Peter Wookey
CHIEF SCIENTIFIC OFFICER AND EXECUTIVE DIRECTOR
Peter has focused on the role of the calcitonin receptor (CT Receptor) in tissues and diseases for over 20 years and has published widely with 58 publications including research papers, reviews, and book chapters. He is inventor on two patents owned by Apop Biosciences.
Peter founded two companies, Welcome Receptor Antibodies Pty Ltd and Apop Biosciences Pty Ltd, the latter to fully commercialise opportunities based on these patents.
Currently a Senior Fellow, in the Department of Medicine-Austin, University of Melbourne where he leads a research team. Peter’s research career began with graduation as a PhD student at the John Curtin School of Medical Research, Australian National University, Canberra.
Our Board
-
Matthew Hoskin
NON-EXECUTIVE CHAIR
Over 25 years experience leading businesses in the healthcare and medical technology sectors in both small and large multinational companies.
Currently a medical technology development and commercialisation consultant.
Also a Non-Executive Director of a regional public hospital and Managing Director of an emerging MedTech company
-
Roland Geitenbeek
NON-EXECUTIVE DIRECTOR
Roland has over 35 years’ experience owning and operating successful businesses, he is also a passionate early stage start up investor with an emphasis on life science, therapeutic and biotech companies.
Being an owner operator provides an understanding and appreciation of the challenges experienced in business, with a sharp commercial focus on achieving key outcomes in a timely manner.
-
Dr Paul Boxer
NON-EXECUTIVE DIRECTOR
Paul is a serial founder, investor with the Melbourne Angels, and philanthropist. He started as a Mech Engineer and rose to Chief Engineer–Compact Cars at GM, becoming an entrepreneur in 1999, and completing a PhD in Artificial Intelligence.
He has extensive experience in lean start-up companies. Founded six successful start-ups, mentored two and exited two (so far). His companies range from engineering robotics, boats and MedTech to AI systems.
who uses our technology
-
Academic Researchers
Academic interest is growing in the field of Programmed Cell Death (PCD), which is involved in the fields of embryonic and foetal development as well as disease in adults. Cell stress, apoptosis, and autophagy are key pathways of PCD, and imaging PCD has become integral to understanding these crucial processes during development and disease. This group includes academic researchers at Universities, Research Institutions and Colleges.
-
Industry Research Groups
These people include biotech researchers working in all areas of drug discovery and development. These researchers rely on cutting edge technologies to identify drug targets involved in specific pathways that could lead to the next blockbuster drug in the clinic. Imaging live cells provides valuable insight during high throughput screening.
-
Commercial Research Groups
Contract Research Organisations involved in assay development and fee for service research. Large pharma conducting drug discovery and development focussing on new and novel drugs, or repurposing of existing therapeutics that involve programmed cell death.